Download PDF
CC BY 4.0 · TH Open 2022; 06(04): e323-e334
DOI: 10.1055/a-1930-6492
Original Article

Does High-Dose Thromboprophylaxis Improve Outcomes in COVID-19 Patients? A Meta-analysis of Comparative Studies

Maha A. T. Elsebaie
1   Department of Hematology and Medical Oncology, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States
,
Binav Baral
1   Department of Hematology and Medical Oncology, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States
,
Mai Elsebaie
2   Faculty of Medicine, Ain Shams University, Cairo, Egypt
,
Trilok Shrivastava
1   Department of Hematology and Medical Oncology, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States
,
Catherine Weir
1   Department of Hematology and Medical Oncology, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States
,
Dennis Kumi
1   Department of Hematology and Medical Oncology, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States
,
Noah W. Birch
1   Department of Hematology and Medical Oncology, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Thromboembolism remains a detrimental complication of novel coronavirus disease (COVID-19) despite the use of prophylactic doses of anticoagulation

Objectives This study aimed to compare different thromboprophylaxis strategies in COVID-19 patients

Methods We conducted a systematic database search until June 30, 2022. Eligible studies were randomized (RCTs) and nonrandomized studies that compared prophylactic to intermediate or therapeutic doses of anticoagulation in adult patients with COVID-19, admitted to general wards or intensive care unit (ICU). Primary outcomes were mortality, thromboembolism, and bleeding events. Data are analyzed separately in RCTs and non-RCTs and in ICU and non-ICU patients.

Results. We identified 682 studies and included 53 eligible studies. Therapeutic anticoagulation showed no mortality benefit over prophylactic anticoagulation in four RCTs (odds ratio [OR] = 0.67, 95% confidence interval [CI], 0.18–2.54). Therapeutic anticoagulation didn't improve mortality in ICU or non-ICU patients. Risk of thromboembolism was significantly lower among non-ICU patients who received enhanced (therapeutic/intermediate) anticoagulation (OR = 0.21, 95% CI, 0.06–0.74). Two additional RCTs (Multiplatform Trial and HEP-COVID), not included in quantitative meta-analysis, analyzed non-ICU patients, and reported a similar benefit with therapeutic-dose anticoagulation. Therapeutic anticoagulation was associated with a significantly higher risk of bleeding events among non-randomized studies (OR = 3.45, 95% CI, 2.32–5.13). Among RCTs, although patients who received therapeutic-dose anticoagulation had higher numbers of bleeding events, these differences were not statistically significant. Studies comparing prophylactic and intermediate-dose anticoagulation showed no differences in primary outcomes.

Conclusion There is a lack of mortality benefit with therapeutic-dose over prophylactic-dose anticoagulation in ICU and non-ICU COVID-19 patients. Therapeutic anticoagulation significantly decreased risk of thromboembolism risk in some of the available RCTs, especially among non-ICU patients. This potential benefit, however, may be counter balanced by higher risk of bleeding. Individualized assessment of patient's bleeding risk will ultimately impact the true clinical benefit of anticoagulation in each patient. Finally, we found no mortality or morbidity benefit with intermediate-dose anticoagulation.

Keywords

thrombosis - bleeding - COVID-19 - thromboprophylaxis - therapeutic anticoagulation

Authors' Contributions

M.A.T.E.: conceptualization, study design, quality assessment, data extraction, data mining, data analysis, manuscript drafting, and manuscript review. B.B.: data extraction, data mining, quality assessment, and manuscript drafting. M.E.: data extraction, data mining, quality assessment, manuscript drafting, and manuscript review. T.S.: data extraction, data mining, manuscript drafting, and manuscript review. C.W.: data extraction, data mining, manuscript drafting, and manuscript review. D.K.: data extraction, data mining, and manuscript drafting. N.B.: conceptualization, study design, manuscript drafting, and manuscript review.


Supplementary Material



Publication History

Received: 16 March 2022

Accepted: 15 August 2022

Accepted Manuscript online:
25 August 2022

Article published online:
19 October 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Han H, Yang L, Liu R. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020; 58 (07) 1116-1120
    CrossrefPubMedGoogle Scholar
  • 2 Frantzeskaki F, Armaganidis A, Orfanos SE. Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation. Respiration 2017; 93 (03) 212-225
    CrossrefPubMedGoogle Scholar
  • 3 Al-Samkari H, Karp Leaf RS, Dzik WH. et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020; 136 (04) 489-500
    CrossrefPubMedGoogle Scholar
  • 4 Jonmarker S, Hollenberg J, Dahlberg M. et al. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. Crit Care 2020; 24 (01) 653
    CrossrefPubMedGoogle Scholar
  • 5 Lavinio A, Ercole A, Battaglini D. et al; collaborators. Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units. Crit Care 2021; 25 (01) 155
    CrossrefPubMedGoogle Scholar
  • 6 Hippensteel JA, LaRiviere WB, Colbert JF, Langouët-Astrié CJ, Schmidt EP. Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol 2020; 319 (02) L211-L217
    CrossrefPubMedGoogle Scholar
  • 7 Bolzetta F, Maselli M, Formilan M. et al. Prophylactic or therapeutic doses of heparins for COVID-19 infection? A retrospective study. Aging Clin Exp Res 2021; 33 (01) 213-217
    CrossrefPubMedGoogle Scholar
  • 8 Cohen SL, Gianos E, Barish MA. et al; Northwell Health COVID-19 Research Consortium. Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients. Thromb Haemost 2021; 121 (08) 1043-1053
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Vizcaychipi MP, Shovlin CL, McCarthy A. et al; Gary Davies on behalf of the ChelWest COVID19 Consortium. Increase in COVID-19 inpatient survival following detection of Thromboembolic and Cytokine storm risk from the point of admission to hospital by a near real time Traffic-light System (TraCe-Tic). Braz J Infect Dis 2020; 24 (05) 412-421
    CrossrefPubMedGoogle Scholar
  • 10 Wijaya I, Andhika R, Huang I. The use of therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19: a systematic review. Clin Appl Thromb Hemost 2020; 26: 1076029620960797
    CrossrefPubMedGoogle Scholar
  • 11 Sridharan GK, Vegunta R, Rokkam VRP. et al. Venous thromboembolism in hospitalized COVID-19 patients. Am J Ther 2020; 27 (06) e599-e610
    CrossrefPubMedGoogle Scholar
  • 12 Patell R, Chiasakul T, Bauer E, Zwicker JI. Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: a pooled analysis. Thromb Haemost 2021; 121 (01) 76-85
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Jorda A, Siller-Matula JM, Zeitlinger M, Jilma B, Gelbenegger G. Anticoagulant treatment regimens in patients with covid-19: a meta-analysis. Clin Pharmacol Ther 2022; 111 (03) 614-623
    CrossrefPubMedGoogle Scholar
  • 14 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8 (05) 336-341
    CrossrefPubMedGoogle Scholar
  • 15 Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. World J Metaanal 2017; 5 (04) 80
    PubMedGoogle Scholar
  • 16 Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323 (7304): 101-105
    CrossrefPubMedGoogle Scholar
  • 17 Pesavento R, Ceccato D, Pasquetto G. et al. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. J Thromb Haemost 2020; 18 (10) 2629-2635
    CrossrefPubMedGoogle Scholar
  • 18 Lawler PR, Goligher EC, Berger JS. et al; ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med 2021; 385 (09) 790-802
    Google Scholar
  • 19 Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135
    CrossrefPubMedGoogle Scholar
  • 20 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21 (11) 1539-1558
    Google Scholar
  • 21 Al-Samkari H, Gupta S, Leaf RK. et al; STOP-COVID Investigators. Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19. Ann Intern Med 2021; 174 (05) 622-632
    CrossrefPubMedGoogle Scholar
  • 22 Atalla E, Zhang R, Shehadeh F. et al. Clinical presentation, course, and risk factors associated with mortality in a severe outbreak of COVID-19 in Rhode Island, USA, April-June 2020. Pathogens 2020; 10 (01) 8
    CrossrefPubMedGoogle Scholar
  • 23 Atallah B, Sadik ZG, Salem N. et al. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients. Anaesthesia 2021; 76 (03) 327-335
    CrossrefPubMedGoogle Scholar
  • 24 Avruscio G, Camporese G, Campello E. et al; COVID-VTE Study Group. COVID-19 and venous thromboembolism in intensive care or medical ward. Clin Transl Sci 2020; 13 (06) 1108-1114
    CrossrefPubMedGoogle Scholar
  • 25 Canoglu K, Saylan B. Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection. Ann Saudi Med 2020; 40 (06) 462-468
    CrossrefPubMedGoogle Scholar
  • 26 Chistolini A, Ruberto F, Alessandri F. et al; Policlinico Umberto I COVID-19 Group. Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19. Br J Haematol 2020; 190 (04) e214-e218
    CrossrefPubMedGoogle Scholar
  • 27 Di Castelnuovo A, Costanzo S, Antinori A. et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study. Thromb Haemost 2021; 121 (08) 1054-1065
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Nadkarni GN, Lala A, Bagiella E. et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 2020; 76 (16) 1815-1826
    CrossrefPubMedGoogle Scholar
  • 29 Fauvel C, Weizman O, Trimaille A. et al; Critical Covid-19 France Investigators. Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. Eur Heart J 2020; 41 (32) 3058-3068
    CrossrefPubMedGoogle Scholar
  • 30 Ferguson J, Volk S, Vondracek T, Flanigan J, Chernaik A. Empiric therapeutic anticoagulation and mortality in critically ill patients with respiratory failure from SARS-CoV-2: a retrospective cohort study. J Clin Pharmacol 2020; 60 (11) 1411-1415
    CrossrefPubMedGoogle Scholar
  • 31 Hanif A, Khan S, Mantri N. et al. Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience. Ann Hematol 2020; 99 (10) 2323-2328
    CrossrefPubMedGoogle Scholar
  • 32 Hsu A, Liu Y, Zayac AS, Olszewski AJ, Reagan JL. Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia. Thromb Res 2020; 196: 375-378
    CrossrefPubMedGoogle Scholar
  • 33 Jimenez-Guiu X, Huici-Sánchez M, Rmera-Villegas A, Izquierdo-Miranda A, Sancho-Cerro A, Vila-Coll R. Deep vein thrombosis in noncritically ill patients with coronavirus disease 2019 pneumonia: deep vein thrombosis in nonintensive care unit patients. J Vasc Surg Venous Lymphat Disord 2021; 9 (03) 592-596
    CrossrefPubMedGoogle Scholar
  • 34 Kessler C, Stricker H, Demundo D. et al. Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis. J Thromb Thrombolysis 2020; 50 (04) 833-836
    CrossrefPubMedGoogle Scholar
  • 35 Klok FA, Kruip MJHA, van der Meer NJM. et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 2020; 191: 148-150
    CrossrefPubMedGoogle Scholar
  • 36 Lynn L, Reyes JA, Hawkins K. et al. The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort. Thromb Res 2021; 197: 65-68
    CrossrefPubMedGoogle Scholar
  • 37 Le Jeune S, Suhl J, Benainous R. et al. High prevalence of early asymptomatic venous thromboembolism in anticoagulated COVID-19 patients hospitalized in general wards. J Thromb Thrombolysis 2021; 51 (03) 637-641
    CrossrefPubMedGoogle Scholar
  • 38 Li M, Gitarts S, Nyabera A. et al. Continuous infusion low-dose unfractionated heparin for the management of hypercoagulability associated with COVID-19. J Pharm Pract 2022; 35 (02) 205-211
    CrossrefPubMedGoogle Scholar
  • 39 Lemos ACB, do Espírito Santo DA, Salvetti MC. et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID). Thromb Res 2020; 196: 359-366
    CrossrefPubMedGoogle Scholar
  • 40 Llitjos JF, Leclerc M, Chochois C. et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020; 18 (07) 1743-1746
    CrossrefPubMedGoogle Scholar
  • 41 Lodigiani C, Iapichino G, Carenzo L. et al; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020; 191: 9-14
    CrossrefPubMedGoogle Scholar
  • 42 Longhitano Y, Racca F, Zanza C. et al. Venous thrombo-embolism in hospitalized SARS-CoV-2 patients treated with three different anticoagulation protocols: prospective observational study. Biology (Basel) 2020; 9 (10) E310
    PubMedGoogle Scholar
  • 43 Lopes RD, de Barros E Silva PGM, Furtado RHM. et al; ACTION Coalition COVID-19 Brazil IV Investigators. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021; 397 (10291): 2253-2263
    CrossrefPubMedGoogle Scholar
  • 44 Ionescu F, Jaiyesimi I, Petrescu I. et al. Association of anticoagulation dose and survival in hospitalized COVID-19 patients: a retrospective propensity score-weighted analysis. Eur J Haematol 2021; 106 (02) 165-174
    CrossrefPubMedGoogle Scholar
  • 45 Meizlish ML, Goshua G, Liu Y. et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. Am J Hematol 2021; 96 (04) 471-479
    CrossrefPubMedGoogle Scholar
  • 46 Middeldorp S, Coppens M, van Haaps TF. et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (08) 1995-2002
    CrossrefPubMedGoogle Scholar
  • 47 Moll M, Zon RL, Sylvester KW. et al. VTE in ICU patients with COVID-19. Chest 2020; 158 (05) 2130-2135
    CrossrefPubMedGoogle Scholar
  • 48 Motta JK, Ogunnaike RO, Shah R. et al. Clinical outcomes with the use of prophylactic versus therapeutic anticoagulation in coronavirus disease 2019. Crit Care Explor 2020; 2 (12) e0309
    CrossrefPubMedGoogle Scholar
  • 49 Musoke N, Lo KB, Albano J. et al. Anticoagulation and bleeding risk in patients with COVID-19. Thromb Res 2020; 196: 227-230
    CrossrefPubMedGoogle Scholar
  • 50 Paolisso P, Bergamaschi L, D'Angelo EC. et al. Preliminary experience with low molecular weight heparin strategy in COVID-19 patients. Front Pharmacol 2020; 11: 1124
    CrossrefPubMedGoogle Scholar
  • 51 Paranjpe I, Fuster V, Lala A. et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 2020; 76 (01) 122-124
    CrossrefPubMedGoogle Scholar
  • 52 Perepu US, Chambers I, Wahab A. et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial. J Thromb Haemost 2021; 19 (09) 2225-2234
    CrossrefPubMedGoogle Scholar
  • 53 Sadeghipour P, Talasaz AH, Rashidi F. et al; INSPIRATION Investigators. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA 2021; 325 (16) 1620-1630
    CrossrefPubMedGoogle Scholar
  • 54 Secco E, Pasqualetto MC, Bombardini T, Picano E, Rigo F. A possible benefit from therapeutic anticoagulation in patients with coronavirus disease 2019: the Dolo hospital experience in Veneto, Italy. Kardiol Pol 2020; 78 (09) 919-921
    CrossrefPubMedGoogle Scholar
  • 55 Shah A, Donovan K, McHugh A. et al. Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study. Crit Care 2020; 24 (01) 561
    CrossrefPubMedGoogle Scholar
  • 56 Trinh MA, Chang DR, Govindarajulu US. et al. Therapeutic anticoagulation is associated with decreased mortality in mechanically ventilated COVID-19 patients. bioRxiv 2020; DOI: 10.1101/2020.05.30.20117929.
    CrossrefPubMedGoogle Scholar
  • 57 Voicu S, Chousterman BG, Bonnin P. et al. Increased anticoagulation reduces proximal deep vein thrombosis in mechanically ventilated COVID-19 patients: venous thrombosis prevention & COVID-19. J Infect 2021; 82 (05) 186-230
    CrossrefPubMedGoogle Scholar
  • 58 Qin W, Dong F, Zhang Z. et al. Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: a cohort study in the early epidemic era. Thromb Res 2021; 198: 19-22
    CrossrefPubMedGoogle Scholar
  • 59 Marcos-Jubilar M, Carmona-Torre F, Vidal R. et al; BEMICOP Investigators. Therapeutic versus prophylactic bemiparin in hospitalized patients with nonsevere COVID-19 pneumonia (BEMICOP study): an open-label, multicenter, randomized, controlled trial. Thromb Haemost 2022; 122 (02) 295-299
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Spyropoulos AC, Goldin M, Giannis D. et al; HEP-COVID Investigators. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: The HEP-COVID randomized clinical trial. JAMA Intern Med 2021; 181 (12) 1612-1620
    CrossrefPubMedGoogle Scholar
  • 61 Sholzberg M, Tang GH, Rahhal H. et al; RAPID trial investigators. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 2021; 375 (2400): n2400
    CrossrefPubMedGoogle Scholar
  • 62 Bikdeli B, Talasaz AH, Rashidi F. et al. Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial. Thromb Haemost 2022; 122 (01) 131-141
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Morici N, Podda G, Birocchi S. et al. Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: the X-COVID-19 randomized trial. Eur J Clin Invest 2022; 52 (05) e13735
    CrossrefPubMedGoogle Scholar
  • 64 Pierce-Williams RAM, Burd J, Felder L. et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study. Am J Obstet Gynecol MFM 2020; 2 (03) 100134
    CrossrefPubMedGoogle Scholar
  • 65 Koleilat I, Galen B, Choinski K. et al. Clinical characteristics of acute lower extremity deep venous thrombosis diagnosed by duplex in patients hospitalized for coronavirus disease 2019. J Vasc Surg Venous Lymphat Disord 2021; 9 (01) 36-46
    CrossrefPubMedGoogle Scholar
  • 66 Cuker A, Tseng EK, Nieuwlaat R. et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Adv 2021; 5 (20) 3951-3959
    CrossrefPubMedGoogle Scholar
  • 67 Cuker A, Tseng EK, Nieuwlaat R. et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Adv 2022; 6 (17) 4915-4923
    CrossrefPubMedGoogle Scholar
  • 68 Cuker A, Tseng EK, Schünemann HJ. et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Adv 2022; 6 (17) 4975-4982
    CrossrefPubMedGoogle Scholar